When Halozyme Therapeutics Inc. received word that the FDA was issuing a complete response letter for HyQ, the news wasn't isolated to just the program that it's developing with Baxter International Inc. The FDA also put a temporary clinical hold on a subcutaneous version of ViroPharma Inc.'s Cinryze (C1 esterase inhibitor [human]). (See BioWorld Today, Aug. 3, 2012.)